A ballot initiative supporters claim will lower drug prices in California is vague and poorly conceived, said a group with a long history of advocating for better cures and treatment for HIV and hepatitis C. Read More »

CVS Health Corp. has announced that its President and CEO Larry Merlo will be giving a speech to investors at the Morgan Stanley Global Healthcare Conference on Sept. 13. Read More »

Program designs synthetic oligonucleotide-based drug candidates for cancer and rare disease treatments. Read More »

Portola Pharmaceuticals Inc. has announced that the Late-Breaking Science Hot Line session at the European Society of Cardiology (ESC) 2016 Congress featured the interim results of its ongoing Phase 3b/4 ANNEXA-4 clinical trial of AndexXa (andexanet alfa). Read More »

New life-saving diagnostic test recognized at the 2016 JOB/ACNBH Conference in Paris, France. Read More »

Adding Prolia to glucocorticoid therapy increases bone mineral density. Read More »

Voters concerned about health topics, especially affordability and accessibility and Medicare. Read More »

Agreement gives Amgen global development and commercial rights to BI 836908 (AMG 420). Read More »

Patent-protected Alzheimer's medication subject of infringement litigation. Read More »

Taiho Ventures today announced that it has invested in Arcus Biosciences, a groundbreaking immuno-oncology company that develops small molecules and antibodies to combine with agents to form its own internal combinations. Read More »

The Journal of Community and Supportive Oncology recently published a study that presented two key research findings dealing with treatment options for breast cancer. Read More »

Mylan NV yesterday announced that its inter-parties review (IPR) proceeding in regard to U.S. Patent No. 8,969,302, which is owned by Yeda Research & Development Co. and licensed to Teva Pharmaceuticals, was ruled in its favor of by the U.S. Patent and Trademark Office (PTO) and found unpatentable. Read More »

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Catalyst Pharmaceuticals Inc. for Firdapse to treat myasthenia gravis (MG).e Read More »

If drug manufacturers ever wonder whether they have a collective image problem, the answer is yes, according to a recent Gallup poll. Read More »

The decision by the FDA was done under accelerated approval with continued approval dependent on consequent trials verifying the clinical benefit of BLINCYTO. Read More »

Vifor Pharma, which is owned by Galenica, will be combined with Relypsa to form an important cardio-renal care provider in the United States. Read More »

Laboratorios Salvat S.A.and Arbor Pharmaceuticals LLC recently partnered on the launch of OTOVEL (ciprofloxacin 0.3% and fluocinolone acetonide 0.025%) otic solution. Read More »

Available in wide range of fluorochromes for research use only. Read More »

Amgen and Servier last week announced that their cardiovascular collaboration has seen an advancement due to Servier deciding to exercise its option for the commercialization of omecamtiv mecarbil in Europe for chronic heart failure. Read More »

Array BioPharma announced last week that its New Drug Application (NDA) for binimetinib has been accepted by the U.S. Food and Drug Administration (FDA). Read More »